

Tuesday, September 26

Bellinzona Institutes of Science building (BIOS+)

14:00-16:00 *Registration and welcome remarks*

Opening lectures

16:00-16:40 **Keynote speaker: Davide Robbiani**
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland
Antibodies against virus and chemokines after COVID-19

16:40-17:20 **Keynote speaker: Christian Klein**
Roche, Zürich, Switzerland
PD-1 cis-targeting of IL2v with the PD1-IL2v immunocytokine to overcome the limitations of aldesleukin and biased IL-2Rbg agonists

Informal, standing dinner (Italian Pizza and drinks) - included with registration fee

Wednesday, September 27

Auditorium Banca Stato

Session 1: Immunotherapy of viral diseases

8:30-9:30 *Registration*

9:30-10:00 **Santiago Gonzalez**
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland
The administration of anti-influenza HA antibodies induces an immunosuppression mechanism that impairs the presentation of antigens by lymph node dendritic cells

10:00-10:20 **Selected abstracts for one oral presentation**

10:20-10:40 *Break*

10:40-11:20 **Keynote speaker: Felix Rey**
Institute Pasteur, Paris, France
Virus structure and function

11:20-11:40 **Selected abstracts for one oral presentation**

11:40-12:20 **Keynote speaker: Eva Harris**
University of California (UC), Berkeley, USA
Virology, pathogenesis, immunology, and epidemiology of flaviviruses

12:20-14:00 *Lunch*

Session 2: Antibody-drug development (Part 1)

- 14:00-14:40 **Keynote speaker: Adriano Aguzzi**
University of Zürich, Zürich, Switzerland
Antibody therapy for prion disease
- 14:40-15:00 **Selected abstracts for one oral presentation**
- 15:00-15:40 **Keynote speaker: Dario Neri**
Philogen & ETH Zürich, Siena & Zürich, Italy & Switzerland
Antibody-toxin conjugates
- 15:40-16:00 **Selected abstracts for one oral presentation**
- 16:00-16:20 **Break**
- 16:20-16:40 **Selected abstracts for one oral presentation**
- 16:40-17:20 **Keynote speaker: Baolin Zhang**
Food and Drug Administration (FDA), Silver Spring, USA
Regulatory aspects in antibody-based therapies

Thursday, September 28

Auditorium Banca Stato

Session 3: Host-directed immunotherapies

- 9:00-9:30 **Nuria Izquierdo-Useros**
IrsiCaixa, Badalona, Spain
When antigen-presenting cells go viral: targeting viral dissemination with anti-Siglec-1 mAbs
- 9:30-9:50 **Selected abstracts for one oral presentation**
- 9:50-10:10 **Selected abstracts for one oral presentation**
- 10:10-10:30 **Break**
- 10:30-11:00 **Sarah Gerlo**
UGent, Gent, Belgium
Targeting cytokine activity: towards applications in infectious disease
- 11:00-11:30 **Stylianos Bournazos**
The Rockefeller University, NY, USA
Protective and pathogenic activities of the IgG Fc domain
- 11:30-11:50 **Selected abstracts for one oral presentation**

11:50-12:10 Selected abstracts for one oral presentation

12:10-14:00 *Lunch*

Session 4: Antibody-drug development (Part 2)

14:00-14:40 **Keynote speaker: Giuseppe Pantaleo**
CHUV, University of Lausanne, Lausanne, Switzerland
Pandemic preparedness antibody development

14:40-15:00 Selected abstracts for one oral presentation

15:00-15:20 Selected abstracts for one oral presentation

15:20-15:50 **Janice Reichert**
The antibody society, USA
Antibody therapeutics for infectious disease: commercial development trends

15:50-16:10 *Break*

16:10-16:40 **Arnaud Avril**
IRBA, Brétigny-sur-Orge, France
Development of antibodies for biodefense. The example of an antibody neutralizing several species of Orthopoxvirus

16:40-17:20 **Keynote speaker: Federica Sallusto**
Institute of Research in Biomedicine (IRB) & ETH Zürich, Bellinzona & Zurich, Switzerland
Antibodies against conserved coronavirus epitopes

Friday, September 29

Auditorium Banca Stato

Session 5: Immunotherapy of non-viral diseases

9:00-9:40 **Keynote speaker: Suzan Rooijackers**
University Medical Center (UMC), Utrecht, Netherlands
Immune response against invading bacteria

9:40-10:00 Selected abstracts for one oral presentation

10:00-10:20 Selected abstracts for one oral presentation

10:20-10:40 *Break*

10:40-11:10 **Fabio Bagnoli**
GSK, Siena, Italy
Immunotherapy against bacterial diseases

Closing lecture

11:10-11:50

Keynote speaker: Davide Corti

Humabs BioMed, a subsidiary of VIR Biotechnology, Bellinzona, Switzerland

Antibodies against infectious diseases

11:50-12:20

Conclusion and remarks